Talphera (NASDAQ:TLPH – Get Free Report) released its earnings results on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.14, Zacks reports.
Talphera Price Performance
Shares of TLPH opened at $0.50 on Tuesday. The company has a market cap of $8.43 million, a PE ratio of -0.72 and a beta of 0.20. The firm has a 50-day moving average of $0.61 and a 200-day moving average of $0.71. Talphera has a one year low of $0.45 and a one year high of $1.27.
Analyst Ratings Changes
A number of brokerages have issued reports on TLPH. RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of Talphera in a research report on Tuesday, January 28th. They issued a “buy” rating and a $4.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Talphera in a report on Tuesday.
Talphera Company Profile
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Read More
- Five stocks we like better than Talphera
- Golden Cross Stocks: Pattern, Examples and Charts
- Palantir Stock Builds Momentum on New Partnership
- What is a SEC Filing?
- Tech Sell-Off Makes Microsoft Stock Look Like a Steal
- What is the MACD Indicator and How to Use it in Your Trading
- Is Now the Right Time to Invest in a Natural Gas ETF?
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
